BioRegenx (BRGX) Stock Price

BioRegenx Price

OTC·CLOSED
0.01USD+0.00 (+0.00 %)
Market closed

Over the last 25 years BioRegenx grew revenue by 16.6% annually, reaching 2.34 M USD. For BioRegenx, the net margin of -985.2% is down versus -67.5% a few years ago. The stock trades about 4,586% above its 52-week low.

BioRegenx stock price

Volume
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of BioRegenx over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how BioRegenx stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing BioRegenx's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

BioRegenx Stock Price History
DateBioRegenx Price
7/24/20260.01 USD
7/23/20260.01 USD
7/22/20260.01 USD
7/21/20260.01 USD
7/20/20260.01 USD
7/17/20260.01 USD
7/16/20260.01 USD
7/15/20260.01 USD
7/14/20260.01 USD
7/13/20260.01 USD
7/10/20260.01 USD
7/9/20260.01 USD
7/8/20260.01 USD
7/7/20260.01 USD
7/6/20260.01 USD
7/3/20260.01 USD
7/2/20260.01 USD
7/1/20260.01 USD
6/30/20260.01 USD
6/29/20260.01 USD
6/26/20260.01 USD
6/25/20260.01 USD
6/24/20260.01 USD
6/23/20260.01 USD
6/22/20260.01 USD
6/19/20260.01 USD
6/18/20260.01 USD
6/17/20260.01 USD
6/16/20260.01 USD
6/15/20260.01 USD
6/12/20260.01 USD
6/11/20260.01 USD
6/10/20260.01 USD
6/9/20260.01 USD
6/8/20260.01 USD
6/5/20260.01 USD
6/4/20260.01 USD
6/3/20260.01 USD
6/2/20260.01 USD
6/1/20260.01 USD
5/29/20260.01 USD
5/28/20260.01 USD
5/27/20260.01 USD
5/26/20260.01 USD
5/22/20260.01 USD
5/21/20260.01 USD
5/20/20260.01 USD
5/19/20260.01 USD
5/18/20260.01 USD
5/15/20260.01 USD
5/14/20260.01 USD
5/13/20260.01 USD
5/8/20260.01 USD
5/7/20260.01 USD
5/6/20260.01 USD
5/5/20260.01 USD
4/30/20260.01 USD
4/27/20260.01 USD
4/23/20260.01 USD
4/21/20260.01 USD
4/20/20260.01 USD
4/15/20260.01 USD
4/13/20260.01 USD
4/8/20260.01 USD
3/31/20260.01 USD
3/30/20260.01 USD
3/25/20260.01 USD
3/24/20260.01 USD
3/20/20260.01 USD
3/17/20260.01 USD
3/13/20260.01 USD
3/11/20260.01 USD
3/10/20260.01 USD
3/5/20260.01 USD
3/3/20260.01 USD
2/24/20260.01 USD
2/23/20260.02 USD
2/20/20260.02 USD
2/19/20260.02 USD
2/18/20260.02 USD
2/13/20260.01 USD
2/11/20260.01 USD
2/10/20260.01 USD
2/5/20260.01 USD
2/2/20260.01 USD
1/29/20260.01 USD
1/23/20260.01 USD
1/20/20260.01 USD
1/16/20260.01 USD
1/12/20260.01 USD
1/6/20260.01 USD
1/5/20260.01 USD
12/31/20250.01 USD
12/30/20250.01 USD
12/26/20250.01 USD
12/22/20250.01 USD
12/18/20250.01 USD
12/17/20250.01 USD
12/16/20250.02 USD
12/12/20250.02 USD
12/11/20250.01 USD
12/10/20250.01 USD
12/9/20250.02 USD
12/3/20250.01 USD
12/2/20250.01 USD
12/1/20250.01 USD
11/26/20250.01 USD
11/25/20250.01 USD
11/24/20250.02 USD
11/21/20250.01 USD
11/19/20250.01 USD
11/14/20250.01 USD
11/12/20250.01 USD
11/10/20250.01 USD
11/6/20250.01 USD
11/4/20250.00 USD
11/3/20250.01 USD
10/31/20250.00 USD
10/29/20250.00 USD
10/28/20250.00 USD
10/24/20250.00 USD
10/22/20250.00 USD
10/20/20250.00 USD
10/17/20250.00 USD
10/16/20250.00 USD
10/15/20250.00 USD
10/7/20250.00 USD
10/3/20250.00 USD
10/1/20250.00 USD
9/30/20250.00 USD
9/25/20250.00 USD
9/24/20250.00 USD
9/23/20250.00 USD
9/22/20250.00 USD
9/18/20250.00 USD
9/17/20250.00 USD
9/16/20250.00 USD
9/12/20250.00 USD
9/11/20250.00 USD
9/9/20250.00 USD
9/8/20250.00 USD
9/5/20250.00 USD
9/4/20250.00 USD
9/2/20250.00 USD
8/29/20250.00 USD
8/27/20250.00 USD
8/22/20250.00 USD
8/21/20250.00 USD
8/19/20250.00 USD
8/15/20250.00 USD
8/14/20250.00 USD
8/13/20250.00 USD
8/12/20250.00 USD
8/8/20250.00 USD
7/31/20250.00 USD
7/30/20250.00 USD
7/29/20250.00 USD
Access this data via the Eulerpool API

BioRegenx Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2002
0.00 USD
-290,000.00 USD
-290,000.00 USD
Jan 1, 2003
0.00 USD
-450,000.00 USD
-450,000.00 USD
Jan 1, 2004
0.00 USD
-220,000.00 USD
-220,000.00 USD
Jan 1, 2020
400,000.00 USD
-210,000.00 USD
-270,000.00 USD
Jan 1, 2021
200,000.00 USD
-170,000.00 USD
-100,000.00 USD
Jan 1, 2022
40,000.00 USD
-80,000.00 USD
-80,000.00 USD
Jan 1, 2023
3.41 M USD
-3.41 M USD
-3.60 M USD
Jan 1, 2024
2.34 M USD
-6.55 M USD
-23.05 M USD

BioRegenx Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 29, 2026, 8:39 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
199819992000200120022003200420202021202220232024
3.002.00
-33.33
66.6750.00
1.001.001.001.001.001.001.001.001.001.002.001.00
-3.00-6.00
-100.00-300.00
-3.00-23.00
666.67
939.51939.51939.51939.51939.510.010.02267.96269.75269.75639.78939.51
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales BioRegenx generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue BioRegenx retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare BioRegenx's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares BioRegenx has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against BioRegenx's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

BioRegenx stock margins

The BioRegenx margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BioRegenx. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BioRegenx.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2002
70.87 %
- %
- %
Jan 1, 2003
70.87 %
- %
- %
Jan 1, 2004
70.87 %
- %
- %
Jan 1, 2020
80.00 %
-52.50 %
-67.50 %
Jan 1, 2021
45.00 %
-85.00 %
-50.00 %
Jan 1, 2022
75.00 %
-200.00 %
-200.00 %
Jan 1, 2023
67.76 %
-99.92 %
-105.53 %
Jan 1, 2024
70.87 %
-279.93 %
-985.17 %

BioRegenx Stock Revenue, EBIT, Earnings per Share

The BioRegenx earnings per share therefore indicates how much revenue BioRegenx has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2002
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2003
0.00 USD
-45.00 USD
-45.00 USD
Jan 1, 2004
0.00 USD
-11.00 USD
-11.00 USD
Jan 1, 2020
0.00 USD
-0.00 USD
-0.00 USD
Jan 1, 2021
0.00 USD
-0.00 USD
-0.00 USD
Jan 1, 2022
0.00 USD
-0.00 USD
-0.00 USD
Jan 1, 2023
0.01 USD
-0.01 USD
-0.01 USD
Jan 1, 2024
0.00 USD
-0.01 USD
-0.02 USD

BioRegenx business model & stock analysis

Findit Inc is a company that was founded in 1998 and is headquartered in Atlanta, Georgia. It specializes in providing online marketing and social media solutions. Findit Inc is a publicly traded company and is listed on the OTC market under the symbol FDIT.

BioRegenx SWOT Analysis

Strengths

Findit Inc has a strong brand reputation in the industry, which enhances its credibility and customer trust.

The company offers a unique and innovative platform that allows users to search and discover various types of content.

Findit Inc has a dedicated and skilled workforce, ensuring efficient operations and prompt customer service.

Weaknesses

The company has limited financial resources, which could restrict its capabilities for expansion and marketing efforts.

Findit Inc heavily relies on a few key clients for a significant portion of its revenue, creating a potential risk if these clients reduce their usage or terminate contracts.

The company's platform may face competition from larger and more established tech companies in the future.

Opportunities

The increasing adoption of social media and content sharing platforms presents an opportunity for Findit Inc to attract a wider user base.

Expansion into international markets can help Findit Inc reach a global audience and diversify its revenue streams.

Continued advancements in technology provide an opportunity for Findit Inc to enhance its platform and offer new features and services.

Threats

The constantly evolving regulatory landscape related to internet content and data privacy poses a threat to Findit Inc's operations and compliance efforts.

Intense competition from other social media and content platforms could lead to reduced market share and user engagement for Findit Inc.

Changes in user preferences and behavior towards content consumption and sharing may impact the demand for Findit Inc's platform.

BioRegenx Eulerpool Fair Value

Details

Fair Value Estimate

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

BioRegenx historical P/E ratio, EBIT multiple, and P/S ratio

BioRegenx annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

BioRegenx shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2002
961.99 M Stocks
Jan 1, 2003
10,000.00 Stocks
Jan 1, 2004
20,000.00 Stocks
Jan 1, 2020
267.96 M Stocks
Jan 1, 2021
269.75 M Stocks
Jan 1, 2022
269.75 M Stocks
Jan 1, 2023
639.78 M Stocks
Jan 1, 2024
939.51 M Stocks

BioRegenx stock splits

In BioRegenx's history, there have been no stock splits.
Price targets and forecasts for BioRegenx are not yet available.

BioRegenx shareholder structure

% Name
20.87900%
RNL Lonepeak Holdings, LLC
RNL Lonepeak Holdings, LLC
20.56830%
Wilshire Holdings Trust
Wilshire Holdings Trust
12.74645%
Hans Vink Beheer BV
Hans Vink Beheer BV
8.81498%
Libertas Trust
Libertas Trust
7.67160%
JARA Trust
JARA Trust
2.16896%
Resides (William R)
Resides (William R)

BioRegenx Executives and Management Board

WR

Mr. William Resides

(56)

Chief Executive Officer, Interim Chief Financial Officer, Director · since 2024

Compensation157,500.00 USD
SB

Ms. Suzanne Bird

(60)

Director

TP

Mr. Thomas Powers

(49)

Director

RJ

Mr. Richard Janney

(66)

Independent Director

Frequently asked questions about BioRegenx

Findit Inc. operates as a social media marketing platform, providing online marketing solutions for businesses. Their business model revolves around offering customized online marketing campaigns to help companies increase their online presence and reach their target audience. Leveraging various tools and technologies, Findit Inc. aims to enhance brand visibility, generate leads, and improve search engine rankings for businesses across different industries. By focusing on effective content marketing, social sharing, and search engine optimization strategies, Findit Inc. helps businesses gain exposure, attract new customers, and ultimately drive sales.

All fundamentals and in-depth analysis of BioRegenx

Our stock analysis for BioRegenx stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioRegenx. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.